CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 240 enrolled
Drug / intervention
Glooko Mobile Insulin Dosing System(MIDS)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03091712
NCT03091712N/ACompleted
CompareCT.gov

Insulin Degludec Titration Using Mobile Insulin Dosing System

Glooko·interventional·Posted Mar 27, 2017·Updated Mar 5, 2020

In Brief

A clinical study evaluating Glooko Mobile Insulin Dosing System(MIDS) for Type 2 Diabetes Mellitus. Completed, enrolled 240 participants across 1 site.

Detailed Summary

This is an open label randomized, controlled, parallel intervention study. Group 1 will receive usual care for insulin degludec titration using the STEP WISE degludec titration algorithm Group 2 will receive Glooko mobile insulin dosing system, using the STEP WISE degludec titration algorithm.An estimated n= 240 subjects with type 2 diabetes will be enrolled in order to obtain approximately 200 evaluable subjects who will complete the 16 week study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedMar 27, 2017
Enrollment StartMay 5, 2017
Primary CompletionAug 8, 2019
Study CompletionSep 15, 2019
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 9.3 years ago

Interventions

Glooko Mobile Insulin Dosing System(MIDS)device

Mobile Insulin Dosing System (MIDS) for all long acting insulin degludec titration management